Welcome to LookChem.com Sign In|Join Free
The company logo of Jiangsu Zenji Pharmaceuticals LTD

Jiangsu Zenji Pharmaceuticals LTD

Post Buying Request
In the shop
In the shop
In the station

Jiangsu Zenji Pharmaceuticals LTD

Business Type:Trading Company

Main Products:
Year Established:
2014
Jiangsu Zenji Pharmaceuticals LTD's promotional picture
Jiangsu Zenji Pharmaceuticals LTD's promotional picture
Jiangsu Zenji Pharmaceuticals LTD's promotional picture

Products Categories

Jiangsu Zenji Pharmaceuticals LTD

Country: China (Mainland)

Business Type:Trading Company

Mobile: +86-19906633110

Tel:

Fax: +86-025-83172562

Province/state: Jiangsu

City: Nanjing

Street: No.5 Xinmofan Road

Contact Suppliers

Company Profile

Business Type:Manufacturers

Year Established:2003

Company Scale:101 - 500

Business Scope:Velpatasvir Ledipasvir Bazedoxifene Acetate Sofosbuvir Peramivir Obeticholic Venetoclax Eribulin Mesylate Palbociclib Rucaparib Phosphate Ezetimibe Bictegravir

Main Markets:North America     Southeast Asia     Africa     Mid East     

Business License:

Tax Registration Certificate:

Organization Code Certificate:

Legal person's id card:

Jiangsu Zenji Pharmaceuticals LTD.is the predecessor of Jiangsu Long Healthcare Limited ,situated in industrial park of Hongze county, Jiangsu province, China. It is 180Km far from Nanjing Airport and 50Km far from Huaian Airport. It was established on April,2003, approved by FDA of Jiangsu in China. Its investment is RMB 80 million. It consists of several pharmaceutical production workshops, one quality center, a R&D center and a pilot test workshop . Except the R&D center, it also has a R&D institute in Nanjing City with the other holders. There are 5 with Doctor degree and 45 stuffs. It provides strong support for the custom R&D. The Company has been approved by State Food and Drug Administration as GMP enterprise in 2006. ZenjiPharma engages in research & development and production of APIs and pharmaceutical intermediates, focuses on digestive system drugs and cardiovascular drugs.

More
RFQ